Author: Ryder Smith

Old Line Spirits in Baltimore has raised $290,000

Old Line Spirits

BALTIMORE, MD.– A Baltimore, Maryland-based liquor distillery has raised $290,000 in debt, according to a Securities and Exchange Commission filing.

Old Line Spirits filed the Form D on April 20. It did not disclose what it intended to do with the proceeds.

Old Line Spirits is a craft distillery located in Baltimore, Maryland, offering whiskey made of 100 percent malted rye.

Mark McLaughlin and Arch Watkins acquired Golden Distillery, located in Seattle, Washington, from Bob Stilnovich. McLaughlin and Watkins moved what is now Old Line Spirits to Baltimore.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell securities.

The form can be found here.

This story is from the Maryland Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

Bethesda-based Crelate raised $1.7 million

CrelateBETHESDA, MD – A Bethesda, Maryland-based company sold $1.7 million in private equity, according to a Securities and Exchange Commission filing. The total filing is for $2.0 million.

Crelate Inc. filed the Form D on Feb. 28. It did not disclose what it would use the proceeds for.

Crelate is a modern talent relationship management company with applicant tracking for recruiters.

Aaron Elder is the CEO of Crelate. Elder served on the board of Celedon Partners before becoming the CEO of Crelate.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.

The form can be found here.

This story is from the Maryland Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

Rexahn Pharma CEO Suzdak sees 23 percent decrease in compensation

Rexahn

ROCKVILLE, MD – Rexahn Pharmaceutical Inc.’s chief executive officer saw a 23 percent decrease in total compensation in the company’s 2016 fiscal year due to a decrease in stock awards, according to a Securities and Exchange Commission filing.

Peter D. Suzdak’s total compensation for the fiscal year totaled $824,091, down from $1.0 million in the company’s 2015 fiscal year. His stock awards declined to $229,581 in fiscal year 2016 from $629,484 in fiscal year 2015.

Suzdak’s salary for fiscal year 2016 was $430,000, the same from his fiscal year 2015 base salary.

Rexahn, which is a clinical stage biopharmaceutical company focused on developing therapeutics for the treatment of cancer, reported no revenue in its 2016 and 2015 fiscal years.

Rexahn’s annual meeting will be Tuesday, April 11, at 8 a.m. Eastern time, at the Radisson Hotel, located at 3 Research Court in Rockville.

The company’s shares closed Feb. 13 at 28 cents, up 6 cents.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

 

 

Supernus receives patent for new drug

Screen Shot 2017-02-12 at 4.46.59 PMROCKVILLE, MD. — A Rockville, Maryland-based pharmaceutical company received a patent from the U.S. Patent and Trademark Office on Feb. 10 for a new once-daily extended-release nerve pain medication and anticonvulsant.

“With eight U.S. patents now in place for Trokendi XR and seven for Oxtellar XR, we believe we have established a very strong intellectual property position for both products,” said Jack A. Khatter, president and CEO of Supernus Pharmaceuticals Inc. “We are committed to expanding and enhancing our patent coverage to provide our products with the protection they deserve.”

Supernus focuses on the development and commercialization of products treating central nervous system diseases.

The company has two products for epilepsy, and is also developing products for the treatment of impulsive aggression in attention-deficit hyperactivity disorder patients and for the treatment of ADHD.

Supernus’ stock price closed at $25.80 on Friday, Feb. 10, up 5 cents.

More information and details on the patent are located here under the filing with the U.S. Patent and Trademark Office.

This story is from the Maryland Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

Baltimore-based AsclepiX seeks $1 million in funding

AsclepiX TherapeuticsBALTIMORE, MD – A Baltimore, Maryland-based biotech company sold $175,000 in a debt offering, according to a Securities and Exchange Commission filing.

AsclepiX Therapeutics filed the Form D on Feb. 9, and said it would like to raise another $825,000.

Wendy Perrow is the CEO of AsclepiX Therapeutics. She is also responsible for managing the company’s business, clinical, financial, licensing and corporate development efforts.

AsclepiX Therapeutics aims to develop new peptide-based drugs to treat ocular diseases.

The form can be found here.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

Follow this website

Get every new post delivered right to your inbox.